Idazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients: A pilot study

Robert E. Litman, Walter W. Hong, Ellen M. Weissman, Tung Ping Su, William Z. Potter, David Pickar

Research output: Contribution to journalArticlepeer-review


Idazoxan, a selective α2-adrenergic antagonist, was added to stable doses of fluphenazine treatment in six patients with schizophrenia who participated in a double-blind, placebo-controlled pharmacologic study. Compared with fluphenazine alone, combining idazoxan (mean dose, 120 mg/day) with fluphenazine (mean dose, 28 mg/day) resulted in a significant decrease in Brief Psychiatric Rating Scale total symptoms(p <0.05). Symptom ratings returned to baseline upon idazoxan discontinuation. No significant effects of idazoxan were observed on fluphenazine levels in plasma or on extrapyramidal symptoms. These pilot data are compatible with the notion that increased noradrenergic neurotransmission may enhance the therapeutic effects of typical neuroleptics in schizophrenia.

Original languageEnglish (US)
Pages (from-to)264-267
Number of pages4
JournalJournal of Clinical Psychopharmacology
Issue number4
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Idazoxan, an α<sub>2</sub> antagonist, augments fluphenazine in schizophrenic patients: A pilot study'. Together they form a unique fingerprint.

Cite this